Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Geron›
Website
AddedFeb 19, 2024
UpdatedJul 22, 2026
Geron

Geron

Public

California-based Geron Corporation is a clinical-stage biopharmaceutical company specializing in hematologic malignancies.

HQ
Menlo Park, CA, US
Founded
1990
Loading
Overview
Compare
Fundraising
Employees
Website

Geron - Website

An index of every page on geron.com, by section.

22 pages across 6 sections · Updated Jul 12, 2026·

Homepage

Geron's front door: current positioning and top-line messaging.

geron.com
  • Homepage

Careers

Open roles and how Geron recruits, straight from the source.

geron.com/careers

TeamJohn Scarlett

Leadership and the people behind Geron, as the company presents them.

  • John Scarlett/leadership/john-scarlett
  • Michelle Robertson/leadership/michelle-robertson
  • Melissa Kelly Behrs/leadership/melissa-kelly-behrs
  • Shannon Odam/leadership/shannon-odam
  • Dawn Schottlandt/leadership/dawn-schottlandt
  • Bryan Ridgell/leadership/bryan-ridgell

About

Company story, mission, and background as Geron tells it.

geron.com/about
  • Responsibility/about/responsibility
  • History/about/history
  • Culture/about/culture
  • Leadership/about/leadership
  • Partnering/about/partnering

ComparisonFavorable Overall Survival of Imetelstat Treated Relapsed Refractory Myelofibrosis Patients Compared with Closely Matched Real World Data

6 comparison pages published by Geron.

  • Favorable Overall Survival of Imetelstat Treated Relapsed Refractory Myelofibrosis Patients Compared with Closely Matched Real World Data
  • A Randomized Open Label Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate 2 or High Risk Myelofibrosis Mf Refractory to Janus Kinase Jak Inhibitor
  • Favorable Overall Survival with Imetelstat in Relapsed Refractory Myelofibrosis Patients Compared with Real World Data
  • Clinical and Biological Characterization of Low Risk Mds Patients According to Ring Sideroblasts Rs Comparison Between the 3 Subgroups in Who2017 Classification Study from the Spanish Mds Registry
  • The Telomerase Inhibitor Imetelstat Differentially Targets Jak2v617f Versus Calr Mutant Myeloproliferative Neoplasm Cells and Inhibits Jak Stat Signaling
  • Analysis of Patient Reported Fatigue in Imerge Phase 3 Trial of Imetelstat vs Placebo in Lower Risk Mds

PrivacyPrivacy Policy

How Geron collects, uses, and safeguards data: the canonical policy set.

geron.com/privacy-policy